Literature DB >> 29955510

Comparison of readmission data between different categories of antipsychotic drugs at a state psychiatric hospital in Oregon.

Joni Baker1, Cydreese Aebi2.   

Abstract

INTRODUCTION: This chart review utilizes readmission rates and mean time to readmission as markers of drug efficacy to compare different categories of long-acting injectable antipsychotics (LAIAs), antipsychotic polypharmacy, and clozapine to oral antipsychotic monotherapy (OM) at a state psychiatric hospital in Oregon (Oregon State Hospital).
METHODS: Charts were reviewed for patients discharged between October 20, 2011, and September 23, 2015, with a diagnosis of schizophrenia spectrum or mood disorder. Admission dates, discharge dates, and discharge antipsychotics were reviewed for each patient dating back to 1991. Discharge antipsychotics were categorized into groupings of LAIAs, antipsychotic polypharmacy, and clozapine and compared with OM to assess readmission data within 1, 3, and 5 years of discharge. The primary end point was readmission rate, measured as a percentage, and the secondary end point was mean time to readmission (MTR), measured in days.
RESULTS: Of 1088 patients reviewed, there were 2031 patient discharges associated with antipsychotic agents and 1258 readmissions. Patients discharged on LAIA monotherapy or clozapine generally had a lower readmission rate, and patients discharged on antipsychotic polypharmacy generally had a higher readmission rate. Statistical significance for these findings varied over time frames and subgroup analyses. The most notable finding for the secondary end point was a significantly shorter MTR for patients discharged on clozapine for all diagnoses and the subgroup analysis of schizoaffective disorder. DISCUSSION: These results are only a reflection of the patient population at this hospital, and additional reviews at other facilities with different patient characteristics could clarify applicability to other patient populations.

Entities:  

Keywords:  antipsychotic drug; antipsychotic polypharmacy; clozapine; long-acting injectable antipsychotic; psychiatric readmission; psychiatric recidivism

Year:  2018        PMID: 29955510      PMCID: PMC6007569          DOI: 10.9740/mhc.2017.05.124

Source DB:  PubMed          Journal:  Ment Health Clin        ISSN: 2168-9709


  5 in total

1.  Rehospitalization rates of patients recently discharged on a regimen of risperidone or clozapine.

Authors:  R R Conley; R C Love; D L Kelly; J J Bartko
Journal:  Am J Psychiatry       Date:  1999-06       Impact factor: 18.112

2.  Time to rehospitalization in patients with schizophrenia discharged on first generation antipsychotics, non-clozapine second generation antipsychotics, or clozapine.

Authors:  Ana Paula Werneck; Jaime Cecilio Hallak; Eduardo Nakano; Helio Elkis
Journal:  Psychiatry Res       Date:  2011-05-18       Impact factor: 3.222

3.  Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials.

Authors:  Taishiro Kishimoto; Alfred Robenzadeh; Claudia Leucht; Stefan Leucht; Koichiro Watanabe; Masaru Mimura; Michael Borenstein; John M Kane; Christoph U Correll
Journal:  Schizophr Bull       Date:  2012-12-17       Impact factor: 9.306

4.  Comparison of SGA oral medications and a long-acting injectable SGA: the PROACTIVE study.

Authors:  Peter F Buckley; Nina R Schooler; Donald C Goff; John Hsiao; Alexander Kopelowicz; John Lauriello; Theo Manschreck; Alan J Mendelowitz; Del D Miller; Joanne B Severe; Daniel R Wilson; Donna Ames; Juan Bustillo; Jim Mintz; John M Kane
Journal:  Schizophr Bull       Date:  2014-05-27       Impact factor: 9.306

5.  Impact of atypical long-acting injectable versus oral antipsychotics on rehospitalization rates and emergency room visits among relapsed schizophrenia patients: a retrospective database analysis.

Authors:  Marie-Hélène Lafeuille; François Laliberté-Auger; Patrick Lefebvre; Christian Frois; John Fastenau; Mei Sheng Duh
Journal:  BMC Psychiatry       Date:  2013-09-10       Impact factor: 3.630

  5 in total
  2 in total

1.  Readmission Rates of Patients Discharged on Antipsychotic Polypharmacy Compared to Antipsychotic Monotherapy.

Authors:  Daniel Greer; Astha Parikh; Humberto R Jimenez
Journal:  Community Ment Health J       Date:  2022-10-15

2.  Polypharmacy in a hospitalized psychiatric population: risk estimation and damage quantification.

Authors:  J Carmona-Huerta; S Castiello-de Obeso; J Ramírez-Palomino; R Duran-Gutiérrez; D Cardona-Muller; F Grover-Paez; P Fernández-Dorantes; R Medina-Dávalos
Journal:  BMC Psychiatry       Date:  2019-02-21       Impact factor: 3.630

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.